Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Carlomagno

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Scientific Reports|August 10, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinasesMarialuisa Moccia, Donglin Yang, Naga Rajiv Lakkaniga, et al.
Cancer Research|June 3, 2004
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cellsDonata Vitagliano, Francesca Carlomagno, Maria Letizia Motti, et al.
The American Journal of Pathology|January 12, 2002
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinomaFulvio Basolo, Riccardo Giannini, Carmen Monaco, et al.
Plos One|June 6, 2015
Identification of Novel Small Molecule Inhibitors of Oncogenic RET KinaseMarialuisa Moccia, Qingsong Liu, Teresa Guida, et al.
Molecular Oncology|December 10, 2013
Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignanciesDaniela Bossi, Francesca Carlomagno, Isabella Pallavicini, et al.
Journal of Medicinal Chemistry|April 17, 2020
Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent PolypharmacologyMarialuisa Moccia, Brendan Frett, Lingtian Zhang, et al.
Oncogene|June 9, 2004
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomasMaria D Castellone, Valentina Guarino, Valentina De Falco, et al.
European Journal of Medicinal Chemistry|May 21, 2025
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitorPhuc Tran, Marialuisa Moccia, Xiuqi Wang, et al.
Molecular Cell|June 10, 2014
NCOA4 transcriptional coactivator inhibits activation of DNA replication originsRoberto Bellelli, Maria Domenica Castellone, Teresa Guida, et al.
Journal of Medicinal Chemistry|January 27, 2022
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding PoseLingtian Zhang, Marialuisa Moccia, David C Briggs, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Scientific Reports|August 10, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinasesMarialuisa Moccia, Donglin Yang, Naga Rajiv Lakkaniga, et al.
Cancer Research|June 3, 2004
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cellsDonata Vitagliano, Francesca Carlomagno, Maria Letizia Motti, et al.
The American Journal of Pathology|January 12, 2002
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinomaFulvio Basolo, Riccardo Giannini, Carmen Monaco, et al.
Plos One|June 6, 2015
Identification of Novel Small Molecule Inhibitors of Oncogenic RET KinaseMarialuisa Moccia, Qingsong Liu, Teresa Guida, et al.
Molecular Oncology|December 10, 2013
Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignanciesDaniela Bossi, Francesca Carlomagno, Isabella Pallavicini, et al.
Journal of Medicinal Chemistry|April 17, 2020
Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent PolypharmacologyMarialuisa Moccia, Brendan Frett, Lingtian Zhang, et al.
Oncogene|June 9, 2004
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomasMaria D Castellone, Valentina Guarino, Valentina De Falco, et al.
European Journal of Medicinal Chemistry|May 21, 2025
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitorPhuc Tran, Marialuisa Moccia, Xiuqi Wang, et al.
Molecular Cell|June 10, 2014
NCOA4 transcriptional coactivator inhibits activation of DNA replication originsRoberto Bellelli, Maria Domenica Castellone, Teresa Guida, et al.
Journal of Medicinal Chemistry|January 27, 2022
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding PoseLingtian Zhang, Marialuisa Moccia, David C Briggs, et al.
Pageof 7